- Key Publications
The Virology Group moved to the Basil Hetzel Institute in January 2010. Professor Eric Gowans and Dr Branka Grubor-Bauk have remained with the group since this time while other original lab members have taken other positions or graduated and accepted positions as post-doctoral researchers around the world. Our current members are listed under the People tab.
Our research is focussed on novel strategies to develop vaccines for hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Consequently, the work involves aspects of:
- molecular biology to generate recombinant DNA vaccines and recombinant viral vector vaccines
- classical virology to culture and quantitate recombinant viruses, and
- immunology to assess the efficacy of the experimental vaccines in animal models
Interested, dedicated postgraduate students who wish to study virology and/or immunology are welcome to join our group. We have 5 PhD students from many regions of the world and thus are truly multicultural.
Read about the Virology Laboratory’s Research in a story “HIV & Hepatitis C Vaccine Breakthrough” on The Hospital Research Foundation’s website. Or watch the video “Vaccination STEM Careers” on the RiAUS Science Channel with Dr Danushka Wijesundara explaining some aspects of their research.
Student Alumni since 2016
|Makutiro Masavuli||PhD, University of Adelaide||2018||Novel DNA vaccine formulations against Hepatitis C Virus||Prof Eric Gowans, Dr Branka Grubor-Bauk and Dr Dan Wijesundara||University of Adelaide full divisional scholarship|
|Jason Gummow||PhD, University of Adelaide||2017 (Dean's Commendation for Doctoral Thesis Excellence)||DNA vaccine targeting and immunomodulation||Prof Eric Gowans & Dr Branka Grubor-Bauk|
|Khamis Tomusange||PhD, University of Adelaide||2016||Systemic and mucosal immunity to HIV||Prof Eric Gowans, Dr Branka Grubor-Bauk & Dr Dan Wijesundara||The Hospital Research Foundation International Scholarship|
|Harshwadhan Jagdale||MResearch, University of Adelaide||2016||Production and characterisation of recombinant porcine adenoviruses||Prof Eric Gowans, Dr Branka Grubor-Bauk & Dr Dan Wijesundara||Australian Centre for HIV and Hepatitis Virology Award|
- DNA and recombinant viral vector vaccines as therapeutic and prophylactic vaccines
- DNA delivery
- DNA as a cytolytic vaccine
- DNA vaccines designed to generate HCV virus-like particles
- Immunological analysis of the efficacy of HCV vaccines
- DNA and recombinant viral vector vaccines as prophylactic vaccines
- Recombinant human rhinoviruses as a novel vaccine for HIV
- Immunological analysis of the efficacy of HIV vaccines
Gargett T, Grubor-Bauk B, Garrod TJ, Yu W, Miller D, Major L, Wesselingh S, Suhrbier A, Gowans EJ. Induction of antigen-positive cell death by the overexpression of Perforin, but not Diphtheria Toxin A, from a DNA vaccine enhances anti-viral immune responses. Immunology and Cell Biology; 2014. 92: 359-367.
Yu W, Grubor-Bauk B, Gargett T, Garrod T, Gowans EJ. A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine; 2014 Jun 5. 32(27):3409-16. doi: 10.1016/j.vaccine.2014.04.014. Epub 2014 Apr 16.
Garrod TJ, Grubor-Bauk B, Gargett T, Li Y, Miller DS, Yu W, Major L, Burrell CJ, Wesselingh S, Suhrbier A, Gowans EJ. Improved vaccine potency of DNA vaccines which encode membrane-bound or secreted forms of heat shock protein 70. European Journal of Immunology; 2014 Apr 10. doi: 10.1002/eji.201343983. [Epub ahead of print]
Tomusange K, Yu W, Suhbier A, Wijesundara D, Grubor-Bauk B, Gowans EJ. Engineering human rhinovirus serotype A1 as a vaccine vector. Virus Res; 2015. 203: 72-76.
Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Mullick R, Brennan AJ, Voskoboinik I, Grubor-Bauk B, and Gowans EJ. A multi-antigenic DNA vaccine that induces broad HCV-specific T-cell responses in mice. J Virol; 2015. 89: 7991-8002.
Grubor-Bauk B, Yu W, Wijesundara D, Gummow J , Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell mediated immunity in mice and pigs. Gene Ther; 2016. 23 (1): 26-37.
|Chief Investigators||Granting Body||Project Title||Total Grant Amount||Funding Period|
|Gowans EJ, Netter HJ||ARC||Antiviral compounds to inhibit the replicase of hepatitis C virus||$55,000pa||2008 – 2010
|Gowans EJ, Loveland B||NHMRC||A novel HCV vaccine||$151,000pa||2009 – 2011
|Gowans EJ, Roberts SK, Loveland B||NHMRC||A new HCV cell therapy||$164,749pa||2009 – 2011
|Gowans EJ, Torresi J, Das S||Australia-India Biotechnology Fund||A vaccine for hepatitis C virus||$100,000pa||2011 – 2013
|Gowans EJ, Grubor-Bauk B||ACH2||Development of a cytolytic HCV vaccine and a novel challenge model to test efficacy||$174,000||2012 – 2013
|Gowans EJ, Wesselingh S||NHMRC||Mucosal immunity to HIV||$188,000pa||2012 - 2014
|Gowans EJ, Grubor-Bauk B||The Hospital Research Foundation (THRF)||Optimisation of HCV vaccine design||$100,000||2014
|Gowans EJ, Roberts-Thomson I, Grubor-Bauk B||The Hospital Research Foundation (THRF)||DNA vaccine therapy for HCV||$300,000||2014 – 2015
|Torresi J, Gowans EJ||NHMRC (#1060436)||A quadrivalent vaccine for hepatitis C||$450,000||2014 – 2016
|Gowans EJ, Torresi J, Das S||AISRF||Approaches to develop an effective HCV vaccine||$200,000||2015 – 2016
|Wijesundara D||The Hospital Research Foundation Early Career Fellowship||Exoploiting cytolytic adjuvants and novel recombinant viral vaccines as a way forward for HIV-1 and HCV vaccine design||$120,000 pa||2015-2018|
|Gowans EJ, Grubor-Bauk B, Wijesundara D||Australian Centre for HIV and Hepatitis Virology||A multigenotypic HCV DNA Vaccine||$85,000||2016-2017|
|Gowans EJ, Grubor-Bauk B, Wijesundara D||National Foundation for Medical Research and Innovation||A DNA vaccine for Zika virus||$293,000||2016-2018|
|Gowans EJ||The Hospital Research Foundation||A DNA vaccine to induce protective neutralizing antibodies to the HIV Tat||$80,000||2017|
|Wijesundara D||The Hospital Research Foundation: Equipment grant||FlowJo software||$7,381||2017|
|Gowans EJ, Wijesundara D, Maddern G||The Hospital Research Foundation||The protective efficacy of cytolytic DNA vaccine for HCV in marmosets: a step towards human clinical trials||$50,000||2017-2018|
|Shrestha A||The Hospital Research Foundation Early Career Fellowship||The development of novel cytolytic DNA vaccine which elicits cellular immunity to conserved viral proteins||$120,000 pa||2017-2019|
|Professor Andrew Abell||Department of Chemistry, University of Adelaide||Adelaide||Australia|
|Associate Professor Renato Morona||Molecular Biosciences, University of Adelaide||Adelaide||Australia|
|Professor Ian Roberts-Thomson||Medicine, University of Adelaide||Adelaide||Australia|
|Associate Professor Michael Beart||Biological Sciences, University of Adelaide||Adelaide||Australia|
|Dr David Shaw||Department of Infectious Diseases, Royal Adelaide Hospital||Adelaide||Australia|
|Professor John Hayball||School of Pharmacy and Medical Sciences, University of South Australia||Adelaide||Australia|
|Associate Professor Jill Car||Flinders University of South Australia||Adelaide||Australia|
|Associate Professor Charani Ranasinghe||Australian National University||Canberra||Australia|
|Associate Professor Joseph Torresi||Doherty Institute||Melbourne||Australia|
|Dr Robert De Rose||Doherty Institute||Melbourne||Australia|
|Professor Margaret Hellard||Burnet Institute||Melbourne||Australia|
|Professor Paul Dietze||Burnet Institute||Melbourne||Australia|
|Professor Melissa Churchill||RMIT University||Melbourne||Australia|
|Professor David Bowen||Centenary Institute||Sydney||Australia|
|Dr Saumitra Das||Indian Institute of Science||Bangalore||India|
|Dr Suresh Tikoo||University of Saskatchewan||Saskatoon||Canada|